What does Rick Pazdur's new role mean for the FDA? And how much credit can the president take for lowering GLP-1 drug prices?
Shares rise 8.5% on enlicitide decanoate Phase 3 data showing LDL reduction. Q3 earnings beat at $2.58/share with $17.3B ...
Merck’s Enlicitide, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with HeFH in Phase 3 ...
Merck & Co. and Bayer’s Verquvo failed to deliver a composite cardiovascular benefit for certain patients with stable heart failure with reduced ejection fraction (HFrEF). The phase 3 Victor trial ...
The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback